A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Malignant Solid Tumors

In brief

The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.

Key facts

Study ID
NCT06499350
Run by
FindCure Biosciences (ZhongShan) Co., Ltd.
People needed
33
Starts
2024-11-13
Expected to finish
2026-10-01
Last updated by the study team
2026-03-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.